Table 1.
Discussion topics identified as relevant to discuss in the first, second and third discussion round
| Topics first round | Votes (n) | Second/third round | |
| First session | Glucocorticoids | 18 | + |
| Outcomes | 16 | + | |
| Stratification | 16 | + | |
| Basket trial | 12 | + | |
| Drug stop | 10 | ||
| Biomarkers/biologically selected* | 9 | ||
| Second session | Recruitment | 11 | + |
| Placebo response | 11 | + | |
| Worth difference | 6 | ||
| Efficacy/effectiveness | 4 | ||
| Oncology/early disease | † | ||
| (Activity measures)† |
*Biomarkers and biologically selected patients were two different topics that were fused by the participants.
†No participant (law of two feet).